Molybdenum

Vitaminas y minerales

Última revisión: 7 de abril de 2026. Enfoque de fuentes: contexto estándar de interpretación de laboratorio, material médico de referencia y orientación clínica o de salud pública cuando corresponde.

¿Qué es Molybdenum?

Molybdenum is an essential trace mineral that functions as a cofactor in the form of molybdopterin (molybdenum cofactor, Moco) for four important enzymes in humans: sulfite oxidase (converts toxic sulfite to sulfate), xanthine oxidase (catalyzes the final steps of purine degradation, producing uric acid), aldehyde oxidase (metabolizes various drugs and endogenous aldehydes), and mitochondrial amidoxime reducing component (mARC, involved in nitric oxide metabolism and drug metabolism). Of these, sulfite oxidase is considered the most physiologically critical, as its absence leads to the most severe clinical consequences.

Molybdenum is widely distributed in the food supply, with legumes (particularly lentils, peas, and beans), grains, nuts, and organ meats being the richest sources. Absorption in the small intestine is highly efficient (40–100%), and homeostasis is maintained primarily through renal excretion, which adjusts rapidly to dietary intake. Clinical deficiency is extraordinarily rare in humans and has been conclusively documented only in a single patient on prolonged molybdenum-free parenteral nutrition and in the rare genetic disorder molybdenum cofactor deficiency. Blood and urine molybdenum measurements are available but rarely clinically indicated.

Por qué importa

Molybdenum's most critical role is enabling sulfite oxidase to detoxify sulfite to sulfate. Sulfite is generated during the metabolism of sulfur-containing amino acids (methionine, cysteine) and is also present in foods and wines as a preservative. Without functional sulfite oxidase, sulfite accumulates to toxic levels, causing severe neurological damage. Xanthine oxidase is clinically relevant because it produces uric acid—the end product of purine metabolism and the molecule that accumulates in gout. Medications like allopurinol and febuxostat work by inhibiting xanthine oxidase. Aldehyde oxidase metabolizes numerous pharmaceutical drugs, making molybdenum indirectly relevant to drug metabolism and pharmacology.

Rangos de referencia normales

Grupo	Rango	Unidad
Adults (serum)	0.1–3.0	µg/L
Adults (urinary excretion)	10–300	µg/day

Los rangos de referencia pueden variar entre laboratorios. Compara siempre tus resultados con los rangos proporcionados por tu laboratorio.

Qué significan los niveles altos de Mo

Causas comunes

Occupational exposure (mining, metallurgy)
Environmental contamination near mining operations
Very high supplemental intake

Posibles síntomas

Gout-like symptoms (elevated uric acid production via xanthine oxidase)
Joint pain and swelling
Possible reproductive effects at very high exposures (animal data)
Gastrointestinal distress

Qué hacer: Molybdenum toxicity from dietary sources is rare. The tolerable upper limit is 2,000 µg/day for adults. If elevated from occupational exposure, reduce or eliminate exposure and monitor uric acid levels, as excess molybdenum can increase uric acid production. Treat gout-like symptoms as appropriate. For environmental contamination, consult occupational or environmental health specialists.

Qué significan los niveles bajos de Mo

Causas comunes

Molybdenum cofactor deficiency (rare autosomal recessive genetic disorder)
Prolonged molybdenum-free parenteral nutrition (single documented case)
Extremely rare dietary deficiency in regions with very low soil molybdenum

Posibles síntomas

Molybdenum cofactor deficiency: severe neonatal seizures, feeding difficulties, lens dislocation (ectopia lentis), progressive neurological deterioration
Acquired deficiency (TPN case): tachycardia, tachypnea, night blindness, irritability, coma
Sulfite accumulation (elevated urinary sulfite)
Low uric acid levels (impaired xanthine oxidase function)

Qué hacer: Acquired dietary molybdenum deficiency is virtually nonexistent in humans eating any reasonable diet. Molybdenum cofactor deficiency is a devastating genetic condition with limited treatment options; cyclic pyranopterin monophosphate (cPMP) replacement therapy has been approved for type A deficiency if administered early. For the single reported acquired case (TPN-related), supplementation with ammonium molybdate resolved symptoms. Ensure parenteral nutrition formulations contain trace amounts of molybdenum.

¿Cuándo se recomienda la prueba de Mo?

When molybdenum cofactor deficiency is suspected in neonates with seizures and low uric acid
In occupational health screening for molybdenum-exposed workers
Rarely indicated for nutritional assessment in clinical practice
When evaluating unexplained low uric acid levels
In research settings studying trace mineral metabolism

Preguntas frecuentes

Molybdenum deficiency is rare for several reasons: it is widely distributed in the food supply, particularly in plant-based foods; the daily requirement is very small (45 µg/day for adults); intestinal absorption is highly efficient (40–100% bioavailability); and the kidneys efficiently adjust excretion to maintain balance. The combination of ubiquitous dietary availability, tiny daily requirements, excellent absorption, and effective renal conservation makes it virtually impossible to become deficient through diet alone. The only clearly documented acquired case occurred in a patient receiving prolonged total parenteral nutrition that lacked molybdenum.

Molybdenum cofactor deficiency (MoCD) is a rare autosomal recessive genetic disorder that prevents the body from synthesizing molybdopterin, the organic molecule that binds molybdenum to create the functional cofactor. Without this cofactor, sulfite oxidase, xanthine oxidase, and aldehyde oxidase are all nonfunctional. The most devastating consequence is sulfite accumulation, which causes severe and progressive brain damage. Affected infants typically present within the first week of life with intractable seizures, feeding difficulties, and progressive encephalopathy. Type A MoCD can now be treated with cyclic pyranopterin monophosphate (Nulibry/fosdenopterin) if diagnosed and treated very early.

Yes, there is a well-established antagonistic interaction between molybdenum and copper, particularly in ruminant animals. In cattle, high dietary molybdenum combined with sulfur forms thiomolybdates in the rumen, which tightly bind copper and prevent its absorption, leading to copper deficiency ("teart" pastures). In humans, this interaction is less clinically significant at normal dietary intakes, but tetrathiomolybdate has been investigated as a pharmaceutical agent to treat Wilson disease (copper overload) by binding excess copper. This therapeutic application leverages the natural copper-antagonizing property of molybdenum-sulfur compounds.

Biomarcadores relacionados

UAÁcido úrico FeHierro sérico CuCopper ZnZinc

Referencias y enfoque de revisión

Las páginas del glosario de biomarcadores son explicaciones educativas y deben interpretarse junto con los rangos de referencia y comentarios proporcionados por tu laboratorio y tu profesional de salud. Para conocer nuestros estándares editoriales y proceso de revisión, consulta nuestra Política editorial y nuestro Proceso de revisión de contenido.

¿Quieres analizar tus niveles de Mo?

Sube tus resultados de laboratorio para recibir un análisis instantáneo con IA de todos tus biomarcadores.

Subir resultados de laboratorio →

Aviso médico: Esta información es solo educativa y no sustituye el consejo, diagnóstico ni tratamiento médico profesional. Los rangos de referencia pueden variar entre laboratorios. Consulta siempre a tu profesional sanitario para interpretar tus resultados concretos.